168,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
Melden Sie sich für den Produktalarm an, um über die Verfügbarkeit des Produkts informiert zu werden.

  • Broschiertes Buch

Biochemistry of Collagens, Laminins, and Elastin: Structure, Function and Biomarkers, Third Edition provides current data on key structural proteins (collagens, laminins, and elastin), reviews on how these molecules affect pathologies, and information on how selected modifications of these proteins can result in altered signaling properties of the original extracellular matrix (ECM). Further, it discusses the novel concept that an increasing number of components of the extracellular matrix harbor cryptic signaling functions with ties to endocrine function, and how this knowledge may be used to…mehr

Produktbeschreibung
Biochemistry of Collagens, Laminins, and Elastin: Structure, Function and Biomarkers, Third Edition provides current data on key structural proteins (collagens, laminins, and elastin), reviews on how these molecules affect pathologies, and information on how selected modifications of these proteins can result in altered signaling properties of the original extracellular matrix (ECM). Further, it discusses the novel concept that an increasing number of components of the extracellular matrix harbor cryptic signaling functions with ties to endocrine function, and how this knowledge may be used to modulate various pathologies, including fibrotic disease. This new edition has been expanded and revised to incorporate recent research advances. Several new chapters explore a range of chronic diseases in which the ECM and collagens, laminin and elastin are central players in disease modulation, including new chapters on lung, skin and intestinal disease, as well as cancers. The new edition also considers emerging analytical technologies that can detect biomarkers of ECM degradation, with discussion of protein quantification and detecting aging of collagens.
Autorenporträt
Morten Karsdal has been CEO of Nordic Bioscience A/S since June 2010. Since 2002, Morten Karsdal has focused his research on the discovery and development of novel biochemical markers. This has resulted in the development of more than 15 ELISA assays for detecting biomarkers that have been used for research in the fields of fibrosis, osteoporosis and osteoarthritis. One of these assays has been 510(k) approved by the Food and Drug Administration (FDA) in the USA.